Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-13 · accession 0000875320-25-000234 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-17 | 2025-11-13+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | M - OptEx | $88.59 | +73.3K | 37.9K | New | +$6.49M |
| DM | 2025-11-17 | 2025-11-13+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale+OE | $440.60 | -73.3K | 24.1K | -75% | -$32.29M |
| DM | 2025-11-17 | 2025-11-13+ | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | M - OptEx | $0.00 | -73.3K | 13.8K | -84% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-13 | M | A | 19,688 | $91.05 | 43,714 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-13 | S | D | 18,528 | $440.22 | 25,186 | D | — | — | (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $440.22 (range $440.00 to $440.99). |
| 3 | Common | Common Stock | 2025-11-13 | S | D | 1,160 | $441.05 | 24,026 | D | — | — | (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $441.05 (range $441.00 to $441.10). |
| 4 | Common | Common Stock | 2025-11-14 | S | D | 40 | $442.00 | 24,026 | D | — | — | |
| 5 | Common | Common Stock | 2025-11-14 | M | A | 39,769 | $86.52 | 77,630 | D | — | — | |
| 6 | Common | Common Stock | 2025-11-14 | S | D | 32,234 | $440.30 | 45,396 | D | — | — | (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $440.30 (range $440.00 to $440.99). |
| 7 | Common | Common Stock | 2025-11-14 | S | D | 21,330 | $441.35 | 24,066 | D | — | — | (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F6) Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99). |
| 8 | Common | Common Stock | 2025-11-14 | M | A | 13,835 | $91.05 | 37,861 | D | — | — | |
| 9 | Derivative | Stock Option (Right to Buy) | 2025-11-14 | M | D | 39,769 | $0.00 | 63,781 | D | $86.52 · — to 2027-02-02 | 39,769 Common Stock | (F7) Fully vested. |
| 10 | Derivative | Stock Option (Right to Buy) | 2025-11-14 | M | D | 13,835 | $0.00 | 1 | D | $91.05 · — to 2026-02-01 | 13,835 Common Stock | (F7) Fully vested. |
| 11 | Derivative | Stock Option (Right to Buy) | 2025-11-13 | M | D | 19,688 | $0.00 | 13,836 | D | $91.05 · — to 2026-02-01 | 19,688 Common Stock | (F7) Fully vested. |